As of 2026-03-22, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 14.8x | 11.3x |
| Forward P/E multiples | 12.2x - 13.7x | 12.6x |
| Fair Price | (138.29) - (155.18) | (134.97) |
| Upside | -180.2% - -190.0% | -178.3% |
| Date | EV/EBITDA |